Drug Trial Radar · NCT06834074
Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Nuvalent Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 19, 2025
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
The Expanded Access Program will provide an alternate mechanism for patients, who lack satisfactory therapeutic alternatives and cannot participate in a neladalkib clinical trial, to access investigational neladalkib.
Conditions
- Non Small Cell Lung Cancer
- ALK-positive Non-small Cell Lung Cancer (NSCLC)
Interventions
NVL-655Drug
Drug: NVL-655
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
50 sites in 12 countries. Site status is shown where the registry gives one.
University Of California Irvine Medical Center
Orange, California · Available
University of Colorado Anschutz School of Medicine
Aurora, Colorado · Available
University of Chicago Medical Center
Chicago, Illinois · Available
Massachusetts General Hospital
Boston, Massachusetts · Available
Dana-Farber Cancer Institute
Boston, Massachusetts · Available
Henry Ford Cancer Institute
Detroit, Michigan · Available
Washington University in St. Louis
St Louis, Missouri · Available
NYU Langone Health
New York, New York · Available
Memorial Sloan Kettering Cancer Center
New York, New York · Available
Duke University
Durham, North Carolina · Available
The Ohio State University
Columbus, Ohio · Available
The University of Texas MD Anderson Cancer Center
Houston, Texas · Available
University of Washington / Fred Hutchinson Cancer Center
Seattle, Washington · Available
Royal North Shore Hospital
St Leonards, New South Wales, Australia · Available
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Available
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Available
Cross Cancer Institute
Edmonton, Alberta, Canada · Available
BC Cancer - Vancouver
Vancouver, British Columbia, Canada · Available
The Ottawa Hospital
Ottawa, Ontario, Canada · Available
Princess Margaret Hospital
Toronto, Ontario, Canada · Available
Centre Leon Berard
Lyon, Auvergne-Rhône-Alpes, France · Available
Institut Gustave Roussy
Villejuif, Île-de-France Region, France · Available
GCS IUCT Oncopole
Toulouse, Occitanie, France · Available
CHU de Nantes
Nantes, Pays de la Loire Region, France · Available
Azienda Ospedaliero Universitaria delle Marche
Ancona, Italy · Available
Istituto Tumori Giovanni Paolo II
Bari, Italy · Available
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy · Available
L'Istituto Europeo di Oncologia S.r.l.
Milan, Italy · Available
IRCCS Istituto Oncologico Veneto
Padova, Italy · Available
AUSL della Romagna - Ravenna
Ravenna, Italy · Available
IRCCS Istituto Nazionale Tumori Regina Elena
Rome, Italy · Available
Antoni van Leeuwenhoek Hospital
Amsterdam, Netherlands · Available
University Medical Center Groningen
Groningen, Netherlands · Available
Stichting Het Nederlands Kanker Instituut
Amsterdam, North Holland, Netherlands · Available
National University Hospital Singapore
Singapore, Singapore · Available
National Cancer Centre Singapore
Singapore, Singapore · Available
Severance Hospital Yonsei University Health System
Seoul, South Korea · Available
Seoul National University Hospital
Seoul, Jongno-gu, South Korea · Available
Gerencia de Gestión Integrada A Coruna
A Coruña, Spain · Available
Uomi Cancer Center-Clinica Tres Torres
Barcelona, Spain · Available
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.